Cardiac hypertrophy
Pro Research Analysisby 
Searched over 200M research papers for "cardiac hypertrophy"
Cardiac Hypertrophy: Definition and Types
Cardiac hypertrophy is an increase in the mass of the heart, most commonly affecting the left ventricle. It can be classified as either physiological or pathological. Physiological hypertrophy occurs in response to normal or beneficial stimuli such as exercise or pregnancy, resulting in moderate heart muscle growth, normal or enhanced contractility, and regression after the stimulus is removed. In contrast, pathological hypertrophy is typically caused by conditions like hypertension, valvular heart disease, or myocardial infarction, leading to excessive heart muscle growth, impaired function, cell death, fibrosis, and often irreversible changes even after the underlying cause is treated 1456+2 MORE.
Mechanisms and Triggers of Cardiac Hypertrophy
Cardiac hypertrophy develops as an adaptation to increased workload on the heart. This can be due to increased afterload (as seen in hypertension), loss of muscle after a heart attack, or hormonal and neural factors such as activation of the sympathetic nervous system or elevated hormone levels. The heart responds by increasing the size of individual cardiomyocytes, not their number, to reduce wall stress and maintain function 3810. Both mechanical stress and neurohormonal signals trigger complex intracellular pathways that regulate protein synthesis, gene expression, and cell growth 3710.
Physiological vs. Pathological Hypertrophy: Key Differences
Physiological hypertrophy is generally adaptive and beneficial, maintaining or improving heart function. It is characterized by normal or increased contractility, absence of fibrosis, and no return to a fetal gene expression pattern. Pathological hypertrophy, however, is maladaptive, often progressing to heart failure. It is marked by reduced contractility, increased fibrosis, cell death, and reactivation of fetal genes. Pathological hypertrophy is also associated with inflammation, capillary loss, and abnormal interactions between heart cells, leading to adverse remodeling and dysfunction 1456+2 MORE.
Molecular and Cellular Pathways in Cardiac Hypertrophy
Multiple signaling pathways regulate cardiac hypertrophy. Key molecular players include protein kinases (such as protein kinase C and MAPKs), transcription factors, and various growth factors. These pathways control gene transcription, protein synthesis, and myofibril assembly in heart cells. Recent research highlights the roles of cellular metabolism, non-coding RNAs, immune responses, and epigenetic modifications in both physiological and pathological hypertrophy. Understanding these pathways has led to the identification of potential therapeutic targets to prevent or reverse pathological hypertrophy 78910.
Clinical Implications and Therapeutic Approaches
While hypertrophy can initially help the heart cope with increased workload, persistent or severe stress can shift the process from adaptive to maladaptive, resulting in heart failure. Clinicians aim to identify and treat patients in the intermediate stage before irreversible pathological changes occur. Modulating hypertrophic signaling without impairing heart function is a promising strategy for preventing and treating heart failure. Advances in understanding the molecular mechanisms of hypertrophy are paving the way for new pharmacological therapies 2478.
Conclusion
Cardiac hypertrophy is a complex process with both adaptive and maladaptive forms. Physiological hypertrophy supports heart function, while pathological hypertrophy leads to dysfunction and heart failure. The transition between these forms depends on the nature and duration of the stress, as well as underlying molecular mechanisms. Ongoing research into the signaling pathways and cellular responses involved in hypertrophy is crucial for developing effective treatments to prevent or reverse heart disease.
Sources and full results
Most relevant research papers on this topic